These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 26967190)

  • 1. 340B Drug Pricing Program Reform.
    Fong WH
    JAMA Oncol; 2016 Mar; 2(3):403. PubMed ID: 26967190
    [No Abstract]   [Full Text] [Related]  

  • 2. 340B Drug Pricing Program Reform-Reply.
    Kantarjian H; Chapman R
    JAMA Oncol; 2016 Mar; 2(3):403-4. PubMed ID: 26967191
    [No Abstract]   [Full Text] [Related]  

  • 3. Value of the 340B Drug Discount Program.
    Kantarjian H; Chapman R
    JAMA Oncol; 2015 Nov; 1(8):1029-30. PubMed ID: 26313652
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of the 340B Drug Pricing Program on Cancer Care Site and Spending in Medicare.
    Jung J; Xu WY; Kalidindi Y
    Health Serv Res; 2018 Oct; 53(5):3528-3548. PubMed ID: 29355925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risks to the 340B Drug Pricing Program Related to Manufacturer Restrictions on Drug Availability.
    Knox RP; Kesselheim AS; Sarpatwari A
    JAMA; 2022 May; 327(17):1647-1648. PubMed ID: 35426909
    [No Abstract]   [Full Text] [Related]  

  • 6. Public referendum on drug prices in the US: will it bring relief?
    Hwang TJ; Kesselheim AS
    BMJ; 2016 Oct; 355():i5657. PubMed ID: 27799143
    [No Abstract]   [Full Text] [Related]  

  • 7. Policy Statement on the 340B Drug Pricing Program by the American Society of Clinical Oncology.
    American Society of Clinical Oncology
    J Oncol Pract; 2014 Jul; 10(4):259-63. PubMed ID: 24737877
    [No Abstract]   [Full Text] [Related]  

  • 8. 340B Drug Pricing Program: The Expansion and Its Effect on Cancer Care.
    Fauer A; Friese CR
    Clin J Oncol Nurs; 2019 Apr; 23(2):217-219. PubMed ID: 30880808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Congress compromises on Medicaid drug pricing; 'best price' excludes VA, others.
    Am J Hosp Pharm; 1993 Jan; 50(1):16, 19. PubMed ID: 8427272
    [No Abstract]   [Full Text] [Related]  

  • 10. Implications of Proposed Medicare Reforms to Counteract High Cancer Drug Prices.
    Mailankody S; Prasad V
    JAMA; 2016 Jul; 316(3):271-2. PubMed ID: 27149663
    [No Abstract]   [Full Text] [Related]  

  • 11. The impact of the 340B Drug Pricing Program on Critical Access Hospitals: Evidence from Medicare Part B.
    Han D
    J Health Econ; 2023 May; 89():102754. PubMed ID: 37030057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicare savings programs: helping those on Medicare pay for health care.
    Reinhard SC; Scala-Foley MA; Caruso JT; Archer D
    Am J Nurs; 2004 Jun; 104(6):62-4. PubMed ID: 15187617
    [No Abstract]   [Full Text] [Related]  

  • 13. Notice regarding Section 602 of the Veterans Health Care Act of 1992; new drug pricing--PHS. Final notice.
    Fed Regist; 1995 Oct; 60(190):51488-9. PubMed ID: 10151188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pricing in the Market for Anticancer Drugs.
    Howard DH; Bach PB; Berndt ER; Conti RM
    J Econ Perspect; 2015; 29(1):139-62. PubMed ID: 28441702
    [No Abstract]   [Full Text] [Related]  

  • 15. Paying for Cancer Drugs That Prove Their Benefit.
    Frank RG; Emanuel EJ
    JAMA; 2021 Oct; 326(16):1579-1580. PubMed ID: 34633420
    [No Abstract]   [Full Text] [Related]  

  • 16. Measuring the Value of New Medications and Implications for Medicare's Proposed Part B Drug Payment Model.
    Hwang TJ; LaMattina JL
    JAMA Oncol; 2016 Sep; 2(9):1125-6. PubMed ID: 27388928
    [No Abstract]   [Full Text] [Related]  

  • 17. Unintended Consequences in Cancer Care Delivery Created by the Medicare Part B Proposal: Is the Clinical Rationale for the Experiment Flawed?
    Gordan L; Grogg A; Blazer M; Fortner B
    J Oncol Pract; 2017 Feb; 13(2):e139-e151. PubMed ID: 28029298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why California's Proposition 61 Was a Bad Idea.
    Yang YT; Chen B; Bennett CL
    Am J Med; 2017 Aug; 130(8):882-884. PubMed ID: 28454905
    [No Abstract]   [Full Text] [Related]  

  • 19. Reimbursing Wisely? CMS's Trial of Medicare Part B Drug Payment Reform.
    Schrag D
    N Engl J Med; 2016 Jun; 374(22):2101-5. PubMed ID: 27248616
    [No Abstract]   [Full Text] [Related]  

  • 20. A comparison of medication access services at 340B and non-340B hospitals.
    Rana I; von Oehsen W; Nabulsi NA; Sharp LK; Donnelly AJ; Shah SD; Stubbings J; Durley SF
    Res Social Adm Pharm; 2021 Nov; 17(11):1887-1892. PubMed ID: 33846100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.